• Collaboration Agreement to Maximise Capabilities of Highly Multiplexed Protein Assays

Mass Spectrometry & Spectroscopy

Collaboration Agreement to Maximise Capabilities of Highly Multiplexed Protein Assays

Apr 18 2013

Agilent Technologies and Applied Proteomics have agreed to collaborate on highly multiplexed protein assays and workflow solutions for multiple reaction monitoring through mass spectrometry. Proteins perform many important cellular functions, are the targets of most drugs and therapies, and are often used as biomarkers for detecting and monitoring disease.

Applied Proteomics will leverage Agilent 6490 Triple Quadrupole MS/MS, 1290 Infinity LC, RapidFire 360 MS system and Bravo liquid-handling technologies to optimise the throughput of highly multiplexed proteomic assays. Multiple reaction monitoring, a highly specific and sensitive mass-spectrometry technique, can detect and quantify analytes from plasma, serum and other biological samples. A multiplex assay can simultaneously measure multiple analytes, such as proteins, peptides, metabolites and lipids.

“The ability to quickly and accurately measure, monitor and analyse a large number of protein biomarkers in a single test has important applications for understanding human diseases and developing new clinical diagnostics,” said John E. Blume, PhD, Chief Science Officer of Applied Proteomics. “Agilent’s innovation in mass spectrometry is an important part of this collaboration as we work together to expand the capabilities of multiplex protein assays.”

Applied Proteomics specialises in a proteomics platform solution with mass spectrometry-based systems control and computational expertise to rapidly collect, process and analyse proteins. Proteomics is the study of the structure and function of proteins and how they interact within a complex biological system.

“We are thrilled to be collaborating with Applied Proteomics, an organisation that has leading expertise in developing mass spectrometry-based methods and instrumentation technologies for protein quantification and proteome applications,” said Can Ozbal, Director of Agilent’s RapidFire business. “Agilent’s innovative automation, measurement and software platforms transform complete workflow solutions from sample preparation through data acquisition, analysis and evaluation in quantitative proteomics and biomarker validation.”


Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions

Events

ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia

Miconex

Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA

EMC2024

Aug 25 2024 Copenhagen, Denmark

View all events